Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT01294787 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD

Interventions

DRUG: indacaterol and glycopyrronium bromide (QVA149)
DRUG: placebo
DRUG: tiotropium

Sponsor

Novartis Pharmaceuticals